Synthetic Biologics Inc (SYN) Releases Earnings Results, Misses Expectations By $0.10 EPS
Synthetic Biologics Inc (NYSEMKT:SYN) issued its earnings results on Wednesday. The company reported ($0.14) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.04) by ($0.10), Bloomberg Earnings reports.
ILLEGAL ACTIVITY WARNING: “Synthetic Biologics Inc (SYN) Releases Earnings Results, Misses Expectations By $0.10 EPS” was posted by American Banking News and is the sole property of of American Banking News. If you are viewing this news story on another domain, it was copied illegally and reposted in violation of US and international copyright legislation. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/11/03/synthetic-biologics-inc-syn-releases-earnings-results-misses-expectations-by-0-10-eps.html.
A number of brokerages have recently commented on SYN. Zacks Investment Research cut shares of Synthetic Biologics from a “buy” rating to a “hold” rating in a research report on Tuesday, October 10th. ValuEngine cut shares of Synthetic Biologics from a “sell” rating to a “strong sell” rating in a research report on Friday, September 1st. One investment analyst has rated the stock with a sell rating, three have given a hold rating and two have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $3.92.
Synthetic Biologics Company Profile
Synthetic Biologics, Inc is a clinical-stage company. The Company is engaged in developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases. The Company’s lead product candidates in Phase II development are SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation (IBS-C), and SYN-004, which is designed to protect the gut microbiome (gastrointestinal (GI) microflora) from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C.
Receive News & Ratings for Synthetic Biologics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synthetic Biologics Inc and related companies with MarketBeat.com's FREE daily email newsletter.